Insight Molecular Diagnostics Inc. Common Stock IMDX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Kitted Products | $24K0.0% | $24K0.0% | $24K0.0% | $24K— | $0— | |
| Laboratory Services | $1.93M-52.2% | $4.03M-7.9% | $4.38M+3.4% | $4.23M+10.1% | $3.84M+107% | |
| Non-Current Assets by Geography | ||||||
| Asia Pacific | $304K-26.0% | $411K-20.7% | $518K— | —— | —— | |
| Europe | $5.94M+5.8% | $5.62M+20.8% | $4.65M— | —— | —— | |
| GB | $1.78M-5.5% | $1.89M+29.8% | $1.46M— | —— | —— | |
| US | $23.29M+7.6% | $21.65M+8.2% | $20.02M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insight Molecular Diagnostics Inc. Common Stock break its business down?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) reports revenue by product across 2 parts — Kitted Products and Laboratory Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Insight Molecular Diagnostics Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insight Molecular Diagnostics Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
